Go Pro
→ Major Buy Alert Issued for August 31st (From TradeSmith) (Ad)tc pixel Free LLY Stock Alerts

Eli Lilly and Company (LLY) Competitors

Eli Lilly and Company logo
$1,184.44 +4.28 (+0.36%)
As of 08/17/2026 03:58 PM Eastern
Compare

LLY vs. AMGN, BIIB, INCY, NVDA, and VKTX

Should you buy Eli Lilly and Company stock or one of its competitors? Eli Lilly and Company's main competitors and comparable companies include Amgen (AMGN), Biogen (BIIB), Incyte (INCY), NVIDIA (NVDA), and Viking Therapeutics (VKTX). Companies are selected based on similarities in market, industry, and size.

How does Eli Lilly and Company compare to Amgen?

Amgen (NASDAQ:AMGN) and Eli Lilly and Company (NYSE:LLY) are both large-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their risk, profitability, earnings, institutional ownership, analyst recommendations, valuation, dividends and media sentiment.

Amgen presently has a consensus price target of $372.39, indicating a potential downside of 11.20%. Eli Lilly and Company has a consensus price target of $1,292.18, indicating a potential upside of 9.10%. Given Eli Lilly and Company's stronger consensus rating and higher probable upside, analysts plainly believe Eli Lilly and Company is more favorable than Amgen.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Amgen
3 Sell rating(s)
15 Hold rating(s)
12 Buy rating(s)
1 Strong Buy rating(s)
2.35
Eli Lilly and Company
1 Sell rating(s)
4 Hold rating(s)
24 Buy rating(s)
1 Strong Buy rating(s)
2.83

Eli Lilly and Company has a net margin of 33.53% compared to Amgen's net margin of 22.95%. Amgen's return on equity of 124.14% beat Eli Lilly and Company's return on equity.

Company Net Margins Return on Equity Return on Assets
Amgen22.95% 124.14% 13.18%
Eli Lilly and Company 33.53%97.83%23.23%

Eli Lilly and Company has higher revenue and earnings than Amgen. Amgen is trading at a lower price-to-earnings ratio than Eli Lilly and Company, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Amgen$36.75B6.17$7.71B$16.0926.06
Eli Lilly and Company$65.18B17.11$20.64B$29.8039.75

Amgen has a beta of 0.41, meaning that its stock price is 59% less volatile than the broader market. Comparatively, Eli Lilly and Company has a beta of 0.51, meaning that its stock price is 49% less volatile than the broader market.

Amgen pays an annual dividend of $10.08 per share and has a dividend yield of 2.4%. Eli Lilly and Company pays an annual dividend of $6.92 per share and has a dividend yield of 0.6%. Amgen pays out 62.6% of its earnings in the form of a dividend. Eli Lilly and Company pays out 23.2% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Amgen has raised its dividend for 14 consecutive years and Eli Lilly and Company has raised its dividend for 11 consecutive years. Amgen is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

76.5% of Amgen shares are held by institutional investors. Comparatively, 82.5% of Eli Lilly and Company shares are held by institutional investors. 0.9% of Amgen shares are held by insiders. Comparatively, 0.1% of Eli Lilly and Company shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Eli Lilly and Company had 86 more articles in the media than Amgen. MarketBeat recorded 126 mentions for Eli Lilly and Company and 40 mentions for Amgen. Amgen's average media sentiment score of 1.21 beat Eli Lilly and Company's score of 0.71 indicating that Amgen is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Amgen
32 Very Positive mention(s)
4 Positive mention(s)
0 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
Eli Lilly and Company
59 Very Positive mention(s)
34 Positive mention(s)
11 Neutral mention(s)
15 Negative mention(s)
5 Very Negative mention(s)
Positive

Summary

Eli Lilly and Company beats Amgen on 14 of the 19 factors compared between the two stocks.

How does Eli Lilly and Company compare to Biogen?

Biogen (NASDAQ:BIIB) and Eli Lilly and Company (NYSE:LLY) are both large-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, analyst recommendations, earnings, dividends, institutional ownership, media sentiment and profitability.

Eli Lilly and Company has a net margin of 33.53% compared to Biogen's net margin of 8.32%. Eli Lilly and Company's return on equity of 97.83% beat Biogen's return on equity.

Company Net Margins Return on Equity Return on Assets
Biogen8.32% 11.18% 6.88%
Eli Lilly and Company 33.53%97.83%23.23%

Biogen has a beta of 0.17, indicating that its stock price is 83% less volatile than the broader market. Comparatively, Eli Lilly and Company has a beta of 0.51, indicating that its stock price is 49% less volatile than the broader market.

In the previous week, Eli Lilly and Company had 116 more articles in the media than Biogen. MarketBeat recorded 126 mentions for Eli Lilly and Company and 10 mentions for Biogen. Biogen's average media sentiment score of 1.29 beat Eli Lilly and Company's score of 0.71 indicating that Biogen is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Biogen
6 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Eli Lilly and Company
59 Very Positive mention(s)
34 Positive mention(s)
11 Neutral mention(s)
15 Negative mention(s)
5 Very Negative mention(s)
Positive

Eli Lilly and Company has higher revenue and earnings than Biogen. Biogen is trading at a lower price-to-earnings ratio than Eli Lilly and Company, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Biogen$9.89B3.12$1.29B$5.6537.02
Eli Lilly and Company$65.18B17.11$20.64B$29.8039.75

Biogen presently has a consensus price target of $227.07, suggesting a potential upside of 8.57%. Eli Lilly and Company has a consensus price target of $1,292.18, suggesting a potential upside of 9.10%. Given Eli Lilly and Company's stronger consensus rating and higher possible upside, analysts plainly believe Eli Lilly and Company is more favorable than Biogen.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Biogen
1 Sell rating(s)
13 Hold rating(s)
18 Buy rating(s)
1 Strong Buy rating(s)
2.58
Eli Lilly and Company
1 Sell rating(s)
4 Hold rating(s)
24 Buy rating(s)
1 Strong Buy rating(s)
2.83

87.9% of Biogen shares are held by institutional investors. Comparatively, 82.5% of Eli Lilly and Company shares are held by institutional investors. 0.3% of Biogen shares are held by insiders. Comparatively, 0.1% of Eli Lilly and Company shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Eli Lilly and Company beats Biogen on 13 of the 16 factors compared between the two stocks.

How does Eli Lilly and Company compare to Incyte?

Eli Lilly and Company (NYSE:LLY) and Incyte (NASDAQ:INCY) are both large-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, valuation, risk, media sentiment, dividends, profitability and analyst recommendations.

Eli Lilly and Company has higher revenue and earnings than Incyte. Incyte is trading at a lower price-to-earnings ratio than Eli Lilly and Company, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Eli Lilly and Company$65.18B17.11$20.64B$29.8039.75
Incyte$5.14B4.87$1.29B$7.8515.73

Eli Lilly and Company has a beta of 0.51, meaning that its stock price is 49% less volatile than the broader market. Comparatively, Incyte has a beta of 0.76, meaning that its stock price is 24% less volatile than the broader market.

Eli Lilly and Company has a net margin of 33.53% compared to Incyte's net margin of 27.71%. Eli Lilly and Company's return on equity of 97.83% beat Incyte's return on equity.

Company Net Margins Return on Equity Return on Assets
Eli Lilly and Company33.53% 97.83% 23.23%
Incyte 27.71%29.93%22.88%

In the previous week, Eli Lilly and Company had 117 more articles in the media than Incyte. MarketBeat recorded 126 mentions for Eli Lilly and Company and 9 mentions for Incyte. Incyte's average media sentiment score of 1.60 beat Eli Lilly and Company's score of 0.71 indicating that Incyte is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Eli Lilly and Company
59 Very Positive mention(s)
34 Positive mention(s)
11 Neutral mention(s)
15 Negative mention(s)
5 Very Negative mention(s)
Positive
Incyte
7 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive

82.5% of Eli Lilly and Company shares are held by institutional investors. Comparatively, 97.0% of Incyte shares are held by institutional investors. 0.1% of Eli Lilly and Company shares are held by company insiders. Comparatively, 16.2% of Incyte shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Eli Lilly and Company currently has a consensus target price of $1,292.18, suggesting a potential upside of 9.10%. Incyte has a consensus target price of $121.65, suggesting a potential downside of 1.50%. Given Eli Lilly and Company's stronger consensus rating and higher possible upside, analysts plainly believe Eli Lilly and Company is more favorable than Incyte.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Eli Lilly and Company
1 Sell rating(s)
4 Hold rating(s)
24 Buy rating(s)
1 Strong Buy rating(s)
2.83
Incyte
0 Sell rating(s)
13 Hold rating(s)
10 Buy rating(s)
0 Strong Buy rating(s)
2.43

Summary

Eli Lilly and Company beats Incyte on 13 of the 17 factors compared between the two stocks.

How does Eli Lilly and Company compare to NVIDIA?

NVIDIA (NASDAQ:NVDA) and Eli Lilly and Company (NYSE:LLY) are related large-cap companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, dividends, valuation, profitability, earnings, institutional ownership and media sentiment.

NVIDIA has a beta of 2.23, indicating that its share price is 123% more volatile than the broader market. Comparatively, Eli Lilly and Company has a beta of 0.51, indicating that its share price is 49% less volatile than the broader market.

NVIDIA has a net margin of 62.97% compared to Eli Lilly and Company's net margin of 33.53%. Eli Lilly and Company's return on equity of 97.83% beat NVIDIA's return on equity.

Company Net Margins Return on Equity Return on Assets
NVIDIA62.97% 96.94% 72.16%
Eli Lilly and Company 33.53%97.83%23.23%

NVIDIA pays an annual dividend of $1.00 per share and has a dividend yield of 0.4%. Eli Lilly and Company pays an annual dividend of $6.92 per share and has a dividend yield of 0.6%. NVIDIA pays out 15.3% of its earnings in the form of a dividend. Eli Lilly and Company pays out 23.2% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. NVIDIA has raised its dividend for 1 consecutive years and Eli Lilly and Company has raised its dividend for 11 consecutive years. Eli Lilly and Company is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

In the previous week, NVIDIA had 235 more articles in the media than Eli Lilly and Company. MarketBeat recorded 361 mentions for NVIDIA and 126 mentions for Eli Lilly and Company. NVIDIA's average media sentiment score of 0.77 beat Eli Lilly and Company's score of 0.71 indicating that NVIDIA is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
NVIDIA
200 Very Positive mention(s)
52 Positive mention(s)
66 Neutral mention(s)
33 Negative mention(s)
8 Very Negative mention(s)
Positive
Eli Lilly and Company
59 Very Positive mention(s)
34 Positive mention(s)
11 Neutral mention(s)
15 Negative mention(s)
5 Very Negative mention(s)
Positive

NVIDIA has higher revenue and earnings than Eli Lilly and Company. NVIDIA is trading at a lower price-to-earnings ratio than Eli Lilly and Company, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NVIDIA$215.94B25.22$120.07B$6.5334.46
Eli Lilly and Company$65.18B17.11$20.64B$29.8039.75

65.3% of NVIDIA shares are owned by institutional investors. Comparatively, 82.5% of Eli Lilly and Company shares are owned by institutional investors. 3.9% of NVIDIA shares are owned by company insiders. Comparatively, 0.1% of Eli Lilly and Company shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

NVIDIA currently has a consensus price target of $305.94, indicating a potential upside of 35.97%. Eli Lilly and Company has a consensus price target of $1,292.18, indicating a potential upside of 9.10%. Given NVIDIA's stronger consensus rating and higher probable upside, analysts clearly believe NVIDIA is more favorable than Eli Lilly and Company.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
NVIDIA
0 Sell rating(s)
2 Hold rating(s)
48 Buy rating(s)
3 Strong Buy rating(s)
3.02
Eli Lilly and Company
1 Sell rating(s)
4 Hold rating(s)
24 Buy rating(s)
1 Strong Buy rating(s)
2.83

Summary

NVIDIA beats Eli Lilly and Company on 14 of the 20 factors compared between the two stocks.

How does Eli Lilly and Company compare to Viking Therapeutics?

Viking Therapeutics (NASDAQ:VKTX) and Eli Lilly and Company (NYSE:LLY) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, earnings, risk, valuation, profitability, institutional ownership and dividends.

Viking Therapeutics presently has a consensus price target of $96.63, indicating a potential upside of 187.32%. Eli Lilly and Company has a consensus price target of $1,292.18, indicating a potential upside of 9.10%. Given Viking Therapeutics' higher possible upside, research analysts clearly believe Viking Therapeutics is more favorable than Eli Lilly and Company.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Viking Therapeutics
2 Sell rating(s)
1 Hold rating(s)
8 Buy rating(s)
1 Strong Buy rating(s)
2.67
Eli Lilly and Company
1 Sell rating(s)
4 Hold rating(s)
24 Buy rating(s)
1 Strong Buy rating(s)
2.83

Eli Lilly and Company has higher revenue and earnings than Viking Therapeutics. Viking Therapeutics is trading at a lower price-to-earnings ratio than Eli Lilly and Company, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Viking TherapeuticsN/AN/A-$359.64M-$4.66N/A
Eli Lilly and Company$65.18B17.11$20.64B$29.8039.75

76.0% of Viking Therapeutics shares are owned by institutional investors. Comparatively, 82.5% of Eli Lilly and Company shares are owned by institutional investors. 5.3% of Viking Therapeutics shares are owned by insiders. Comparatively, 0.1% of Eli Lilly and Company shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Viking Therapeutics has a beta of 0.69, indicating that its share price is 31% less volatile than the broader market. Comparatively, Eli Lilly and Company has a beta of 0.51, indicating that its share price is 49% less volatile than the broader market.

Eli Lilly and Company has a net margin of 33.53% compared to Viking Therapeutics' net margin of 0.00%. Eli Lilly and Company's return on equity of 97.83% beat Viking Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Viking TherapeuticsN/A -94.56% -82.75%
Eli Lilly and Company 33.53%97.83%23.23%

In the previous week, Eli Lilly and Company had 117 more articles in the media than Viking Therapeutics. MarketBeat recorded 126 mentions for Eli Lilly and Company and 9 mentions for Viking Therapeutics. Eli Lilly and Company's average media sentiment score of 0.71 beat Viking Therapeutics' score of 0.24 indicating that Eli Lilly and Company is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Viking Therapeutics
1 Very Positive mention(s)
2 Positive mention(s)
1 Neutral mention(s)
3 Negative mention(s)
0 Very Negative mention(s)
Neutral
Eli Lilly and Company
59 Very Positive mention(s)
34 Positive mention(s)
11 Neutral mention(s)
15 Negative mention(s)
5 Very Negative mention(s)
Positive

Summary

Eli Lilly and Company beats Viking Therapeutics on 12 of the 15 factors compared between the two stocks.

Get Eli Lilly and Company News Delivered to You Automatically

Sign up to receive the latest news and ratings for LLY and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LLY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

LLY vs. The Competition

Export
MetricEli Lilly and CompanyPharmaceuticals IndustryHealthcare SectorNYSE Exchange
Market Cap$1.11T$11.84B$7.03B$24.35B
Dividend Yield0.59%2.69%2.56%3.69%
P/E Ratio39.75779.61270.8630.51
Price / Sales17.11747.21605.4820.17
Price / Cash46.9515.0328.8720.48
Price / Book42.2010.4011.094.92
Net Income$20.64B$2.78B$3.45B$1.07B
7 Day Performance-2.35%1.01%0.62%0.13%
1 Month Performance0.55%0.22%2.09%2.60%
1 Year Performance69.47%144.11%61.59%18.42%

Eli Lilly and Company Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
LLY
Eli Lilly and Company
4.8359 of 5 stars		$1,184.44
+0.4%		$1,292.18
+9.1%		+68.8%$1.11T$65.18B39.7550,000
AMGN
Amgen
3.8374 of 5 stars		$410.95
+1.5%		$370.07
-9.9%		+41.5%$222.17B$36.75B25.5431,500
BIIB
Biogen
4.0283 of 5 stars		$207.94
+0.8%		$224.61
+8.0%		+50.9%$30.72B$9.89B36.807,500
INCY
Incyte
3.6134 of 5 stars		$120.56
+1.8%		$120.40
-0.1%		+42.1%$24.44B$5.14B15.362,844
NVDA
NVIDIA
4.9961 of 5 stars		$223.96
+2.3%		$304.26
+35.9%		+24.7%$5.42T$215.94B34.3042,000

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NYSE:LLY) was last updated on 8/18/2026 by MarketBeat.com Staff.
From Our Partners
The retirement stock I'd buy before Nvidia today
In 2014, Marc Chaikin pointed readers toward Nvidia. Now the 60-year Wall Street veteran and creator of the Ch...
Chaikin Analytics | Sponsoredtc pixel
They didn't warn anyone in 1971. This time someone is warning you.
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Iran War: What Happened at 1:11 P.M. Outside D.C.?
A source with ties to Saudi Arabia, the UAE, and the U.S. State Department revealed details of a potential 7 t...
Banyan Hill Publishing | Sponsoredtc pixel
The cat is out the bag
Almost 80,000 tech jobs vanished in the first three months of 2026. Meta cut 14,000 roles, Microsoft offered s...
Porter & Company | Sponsoredtc pixel
A Dark Day Is Coming to America
Keith Kaplan, CEO of TradeSmith, has spent more than $17 million studying AI since 2022. He says a major shift...
TradeSmith | Sponsoredtc pixel
Gold Miners Post Record Cash Flow Even as Prices Pull Back
The four largest gold miners are generating record free cash flow, even with gold pulling back from recent hig...
Golden Portfolio | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
NVIDIA Is 27X Bigger Than One of His "Price Killers"
A little-known company has quietly built a proprietary machine-learning platform trained on 15 years of data f...
The Oxford Club | Sponsoredtc pixel